dear fellow Fools,as promised earlier, here are the clinical data:http://www.exelixis.com/investors-media/press-releases?cpurl...From my point of view it looks quite promising, as all 24 evaluable patients had a decrease in tumor size from baseline.But we have to be aware that...1) the sample size is small2) duration of treatment is short3) net effect of XL518 in this combo4) what means exactly "evaluable patient" ? were there non-evaluable patients ? (obviously the study was not performed according to an intent-to-treat design...)if I can grab more news, you will find them here.marsuculix
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Rat